Treatment of Severe Atopic Dermatitis with Omalizumab: Experience of a Portuguese Immunoallergology Department
Methods Twenty-four patients (14 male 10 female) 30,8 year-old average with severe AD,allergic respiratory disease and high levels of IgE (>2000 UI/L) not responding to conventional therapies were proposed for omalizumab treatment.They were evaluated for SCORAD index and daily/rescue medication b...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2016-02, Vol.137 (2), p.AB149-AB149 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | AB149 |
|---|---|
| container_issue | 2 |
| container_start_page | AB149 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 137 |
| creator | Mendes, Ana M., MD Pestana, Leticia, MD Aguiar, Rita, MD Costa, Ana Célia, MSc Pedro, Elisa, MD Lopes, Anabela, MD Spinola Santos, Maria A., MD Alonso, Estrella, MD Pereira-Barbosa, M.A., PhD |
| description | Methods Twenty-four patients (14 male 10 female) 30,8 year-old average with severe AD,allergic respiratory disease and high levels of IgE (>2000 UI/L) not responding to conventional therapies were proposed for omalizumab treatment.They were evaluated for SCORAD index and daily/rescue medication before,during and after treatment.Omalizumab was administrated subcutaneously at doses range from 150 to 600 mg every 2 weeks for 19,6 months average treatment. |
| doi_str_mv | 10.1016/j.jaci.2015.12.616 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1765330359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674915023581</els_id><sourcerecordid>3953704081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2726-73f77d3063283d2f5b90de6dd2c211a48e407dc858a48aef1b303167da40bdeb3</originalsourceid><addsrcrecordid>eNp9kU9r3DAQxUVpodu0X6AnQc529Wct2SUEQpqkgUAKSc9ClsZbubblSHLazaePnC0UeuhpZuD9Zh5vEPpISUkJFZ_6stfGlYzQqqSsFFS8QhtKGlmImlWv0YaQhhZCbpu36F2MPckzr5sNmu4D6DTClLDv8B08QgB8lvzsDP4CYdTJJRfxL5d-4NtRD-5pGXX7GV_8niE4mAysnMbffEjLboEI-Hocl8nrYYCw84Pf7fOiWYeXI-_Rm04PET78qUfo--XF_fnX4ub26vr87KYwTDJRSN5JaTkRnNXcsq5qG2JBWMsMo1Rva9gSaU1d1bnX0NGWE06FtHpLWgstP0LHh71z8A_ZVVK9X8KUTyoqRcWzvGqyih1UJvgYA3RqDm7UYa8oUWuuqldrrmrNVVGmcq4ZOjlAkP0_OggqmpcgrAtgkrLe_R8__Qc3g5uc0cNP2EP8a1NFpoi6Wx-3_o1WhPGqpvwZGdeXSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1765330359</pqid></control><display><type>article</type><title>Treatment of Severe Atopic Dermatitis with Omalizumab: Experience of a Portuguese Immunoallergology Department</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mendes, Ana M., MD ; Pestana, Leticia, MD ; Aguiar, Rita, MD ; Costa, Ana Célia, MSc ; Pedro, Elisa, MD ; Lopes, Anabela, MD ; Spinola Santos, Maria A., MD ; Alonso, Estrella, MD ; Pereira-Barbosa, M.A., PhD</creator><creatorcontrib>Mendes, Ana M., MD ; Pestana, Leticia, MD ; Aguiar, Rita, MD ; Costa, Ana Célia, MSc ; Pedro, Elisa, MD ; Lopes, Anabela, MD ; Spinola Santos, Maria A., MD ; Alonso, Estrella, MD ; Pereira-Barbosa, M.A., PhD</creatorcontrib><description>Methods Twenty-four patients (14 male 10 female) 30,8 year-old average with severe AD,allergic respiratory disease and high levels of IgE (>2000 UI/L) not responding to conventional therapies were proposed for omalizumab treatment.They were evaluated for SCORAD index and daily/rescue medication before,during and after treatment.Omalizumab was administrated subcutaneously at doses range from 150 to 600 mg every 2 weeks for 19,6 months average treatment.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2015.12.616</identifier><language>eng</language><publisher>St. Louis: Elsevier Inc</publisher><subject>Allergies ; Allergy and Immunology ; Dermatitis ; Patients</subject><ispartof>Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB149-AB149</ispartof><rights>2016</rights><rights>Copyright Elsevier Limited Feb 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2726-73f77d3063283d2f5b90de6dd2c211a48e407dc858a48aef1b303167da40bdeb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091674915023581$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids></links><search><creatorcontrib>Mendes, Ana M., MD</creatorcontrib><creatorcontrib>Pestana, Leticia, MD</creatorcontrib><creatorcontrib>Aguiar, Rita, MD</creatorcontrib><creatorcontrib>Costa, Ana Célia, MSc</creatorcontrib><creatorcontrib>Pedro, Elisa, MD</creatorcontrib><creatorcontrib>Lopes, Anabela, MD</creatorcontrib><creatorcontrib>Spinola Santos, Maria A., MD</creatorcontrib><creatorcontrib>Alonso, Estrella, MD</creatorcontrib><creatorcontrib>Pereira-Barbosa, M.A., PhD</creatorcontrib><title>Treatment of Severe Atopic Dermatitis with Omalizumab: Experience of a Portuguese Immunoallergology Department</title><title>Journal of allergy and clinical immunology</title><description>Methods Twenty-four patients (14 male 10 female) 30,8 year-old average with severe AD,allergic respiratory disease and high levels of IgE (>2000 UI/L) not responding to conventional therapies were proposed for omalizumab treatment.They were evaluated for SCORAD index and daily/rescue medication before,during and after treatment.Omalizumab was administrated subcutaneously at doses range from 150 to 600 mg every 2 weeks for 19,6 months average treatment.</description><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Dermatitis</subject><subject>Patients</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kU9r3DAQxUVpodu0X6AnQc529Wct2SUEQpqkgUAKSc9ClsZbubblSHLazaePnC0UeuhpZuD9Zh5vEPpISUkJFZ_6stfGlYzQqqSsFFS8QhtKGlmImlWv0YaQhhZCbpu36F2MPckzr5sNmu4D6DTClLDv8B08QgB8lvzsDP4CYdTJJRfxL5d-4NtRD-5pGXX7GV_8niE4mAysnMbffEjLboEI-Hocl8nrYYCw84Pf7fOiWYeXI-_Rm04PET78qUfo--XF_fnX4ub26vr87KYwTDJRSN5JaTkRnNXcsq5qG2JBWMsMo1Rva9gSaU1d1bnX0NGWE06FtHpLWgstP0LHh71z8A_ZVVK9X8KUTyoqRcWzvGqyih1UJvgYA3RqDm7UYa8oUWuuqldrrmrNVVGmcq4ZOjlAkP0_OggqmpcgrAtgkrLe_R8__Qc3g5uc0cNP2EP8a1NFpoi6Wx-3_o1WhPGqpvwZGdeXSQ</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Mendes, Ana M., MD</creator><creator>Pestana, Leticia, MD</creator><creator>Aguiar, Rita, MD</creator><creator>Costa, Ana Célia, MSc</creator><creator>Pedro, Elisa, MD</creator><creator>Lopes, Anabela, MD</creator><creator>Spinola Santos, Maria A., MD</creator><creator>Alonso, Estrella, MD</creator><creator>Pereira-Barbosa, M.A., PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20160201</creationdate><title>Treatment of Severe Atopic Dermatitis with Omalizumab: Experience of a Portuguese Immunoallergology Department</title><author>Mendes, Ana M., MD ; Pestana, Leticia, MD ; Aguiar, Rita, MD ; Costa, Ana Célia, MSc ; Pedro, Elisa, MD ; Lopes, Anabela, MD ; Spinola Santos, Maria A., MD ; Alonso, Estrella, MD ; Pereira-Barbosa, M.A., PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2726-73f77d3063283d2f5b90de6dd2c211a48e407dc858a48aef1b303167da40bdeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Dermatitis</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mendes, Ana M., MD</creatorcontrib><creatorcontrib>Pestana, Leticia, MD</creatorcontrib><creatorcontrib>Aguiar, Rita, MD</creatorcontrib><creatorcontrib>Costa, Ana Célia, MSc</creatorcontrib><creatorcontrib>Pedro, Elisa, MD</creatorcontrib><creatorcontrib>Lopes, Anabela, MD</creatorcontrib><creatorcontrib>Spinola Santos, Maria A., MD</creatorcontrib><creatorcontrib>Alonso, Estrella, MD</creatorcontrib><creatorcontrib>Pereira-Barbosa, M.A., PhD</creatorcontrib><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mendes, Ana M., MD</au><au>Pestana, Leticia, MD</au><au>Aguiar, Rita, MD</au><au>Costa, Ana Célia, MSc</au><au>Pedro, Elisa, MD</au><au>Lopes, Anabela, MD</au><au>Spinola Santos, Maria A., MD</au><au>Alonso, Estrella, MD</au><au>Pereira-Barbosa, M.A., PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Severe Atopic Dermatitis with Omalizumab: Experience of a Portuguese Immunoallergology Department</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>2016-02-01</date><risdate>2016</risdate><volume>137</volume><issue>2</issue><spage>AB149</spage><epage>AB149</epage><pages>AB149-AB149</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Methods Twenty-four patients (14 male 10 female) 30,8 year-old average with severe AD,allergic respiratory disease and high levels of IgE (>2000 UI/L) not responding to conventional therapies were proposed for omalizumab treatment.They were evaluated for SCORAD index and daily/rescue medication before,during and after treatment.Omalizumab was administrated subcutaneously at doses range from 150 to 600 mg every 2 weeks for 19,6 months average treatment.</abstract><cop>St. Louis</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jaci.2015.12.616</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB149-AB149 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_journals_1765330359 |
| source | Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Allergies Allergy and Immunology Dermatitis Patients |
| title | Treatment of Severe Atopic Dermatitis with Omalizumab: Experience of a Portuguese Immunoallergology Department |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T03%3A48%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Severe%20Atopic%20Dermatitis%20with%20Omalizumab:%20Experience%20of%20a%20Portuguese%20Immunoallergology%20Department&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Mendes,%20Ana%20M.,%20MD&rft.date=2016-02-01&rft.volume=137&rft.issue=2&rft.spage=AB149&rft.epage=AB149&rft.pages=AB149-AB149&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2015.12.616&rft_dat=%3Cproquest_cross%3E3953704081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1765330359&rft_id=info:pmid/&rft_els_id=S0091674915023581&rfr_iscdi=true |